APA (7th ed.) Citation

Zimmer, L., Hassel, J. C., & Schadendorf, D. (2020). Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): A randomised, double-blind, placebo-controlled, phase 2 trial. The lancet, 395(10236), . https://doi.org/10.1016/S0140-6736(20)30417-7

Chicago Style (17th ed.) Citation

Zimmer, Lisa, Jessica C. Hassel, and Dirk Schadendorf. "Adjuvant Nivolumab Plus Ipilimumab or Nivolumab Monotherapy Versus Placebo in Patients with Resected Stage IV Melanoma with No Evidence of Disease (IMMUNED): A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial." The Lancet 395, no. 10236 (2020). https://doi.org/10.1016/S0140-6736(20)30417-7.

MLA (9th ed.) Citation

Zimmer, Lisa, et al. "Adjuvant Nivolumab Plus Ipilimumab or Nivolumab Monotherapy Versus Placebo in Patients with Resected Stage IV Melanoma with No Evidence of Disease (IMMUNED): A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial." The Lancet, vol. 395, no. 10236, 2020, https://doi.org/10.1016/S0140-6736(20)30417-7.